Name: Neurometabolic Disorders Market Size, Share, Industry, Forecast and outlook (2024-2031)
Brand: DataM Intelligence
SKU: PH1483
Price: 4350 USD
Availability: InStock

Neurometabolic Disorders Market Size, Share, Growth & Report 2024-2031

Neurometabolic Disorders Market Size, Share, Industry, Forecast and outlook (2024-2031)

<h2>Global Neurometabolic Disorders Market is segmented By Disease Type (Amino Acid Disorders&nbsp;(Phenylketonuria, Maple Syrup Urine Disease, Others),&nbsp;Carbohydrate Metabolism Disorders (Diabetes), Mitochondrial Disorders (Friedreich Ataxia, Wilson Disease), Peroxisomal Disorders (Zellweger Syndrome, Adrenoleukodystrophy), Lysosomal Storage Disorders (Hunter Syndrome, Gaucher Disease, Fabry Disease, Others (Krabbe Disease, Tay-Sachs Disease, Niemann-Pick Disease)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2024-2031</h2>

&nbsp;

<h3>Report Overview</h3>

<blockquote>
The Global &quot;Neurometabolic Disorders Market&quot;&nbsp;is expected to grow at a high CAGR&nbsp;during the forecast&nbsp;period (2024-2031).
</blockquote>

<ol>
	<li>
	<h3>Methodology and Scope</h3>

	<ol>
		<li>
		Research Methodology
		</li>
		<li>
		Research Objective and Scope of the Report
		</li>
	</ol>
	</li>
	<li>
	<h3>Market Definition and Overview</h3>
	</li>
	<li>
	<h3>Executive Summary</h3>

	<ol>
		<li>
		&nbsp;Market Snippet by Disease Type
		</li>
		<li>
		Market Snippet by Region
		</li>
		<li>
		DataM CLO Scenario
		</li>
	</ol>
	</li>
	<li>
	<h3>Market Dynamics</h3>

	<ol>
		<li>
		Market Impacting Factors

		<ol>
			<li>
			Drivers

			<ol>
				<li>
				Increase in prevalence of neurometabolic disorders
				</li>
				<li>
				Technological advancements
				</li>
				<li>
				Supportive government policies
				</li>
			</ol>
			</li>
			<li>
			Restraints

			<ol>
				<li>
				High R&amp;D investments&nbsp;
				</li>
				<li>
				High cost of drugs
				</li>
			</ol>
			</li>
			<li>
			Opportunity
			</li>
			<li>
			Impact Analysis
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Industry Analysis&nbsp;</h3>

	<ol>
		<li>
		Porter&#39;s Five Forces Analysis
		</li>
		<li>
		Regulatory Analysis
		</li>
		<li>
		Epidemiology
		</li>
	</ol>
	</li>
	<li>
	<h3>By Disease Type</h3>

	<ol>
		<li>
		Introduction

		<ol>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
			<li>
			Market Attractiveness Index, By Disease Type
			</li>
		</ol>
		</li>
		<li>
		Amino Acid Disorders

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%)
			</li>
			<li>
			Phenylketonuria
			</li>
			<li>
			Maple Syrup Urine Disease
			</li>
			<li>
			Others
			</li>
		</ol>
		</li>
		<li>
		&nbsp;Carbohydrate Metabolism Disorders

		<ol>
			<li>
			Diabetes
			</li>
		</ol>
		</li>
		<li>
		Mitochondrial Disorders

		<ol>
			<li>
			Friedreich Ataxia
			</li>
			<li>
			Wilson Disease
			</li>
		</ol>
		</li>
		<li>
		&nbsp;Peroxisomal Disorders

		<ol>
			<li>
			Zellweger Syndrome
			</li>
			<li>
			Adrenoleukodystrophy
			</li>
		</ol>
		</li>
		<li>
		Lysosomal Storage Disorders

		<ol>
			<li>
			Hunter Syndrome
			</li>
			<li>
			Gaucher Disease
			</li>
			<li>
			&nbsp;Fabry Disease
			</li>
			<li>
			Others (Krabbe Disease, Tay-Sachs Disease, Niemann-Pick Disease)
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>By Region</h3>

	<ol>
		<li>
		Introduction&nbsp;

		<ol>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
			</li>
			<li>
			Market Attractiveness Index, By Region
			</li>
		</ol>
		</li>
		<li>
		North America

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				U.S.
				</li>
				<li>
				Canada
				</li>
				<li>
				Mexico
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		Europe

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				Germany
				</li>
				<li>
				U.K.
				</li>
				<li>
				France
				</li>
				<li>
				Italy
				</li>
				<li>
				Spain
				</li>
				<li>
				Rest of Europe
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		South America

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				Brazil
				</li>
				<li>
				Argentina
				</li>
				<li>
				Rest of South America
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		Asia Pacific

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				China
				</li>
				<li>
				India
				</li>
				<li>
				Japan
				</li>
				<li>
				Australia
				</li>
				<li>
				Rest of Asia Pacific
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		Middle East and Africa

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Global Market Competitive Landscape</h3>

	<ol>
		<li>
		Competitive Scenario
		</li>
		<li>
		Competitor Neurometabolic Disorders Strategy Analysis
		</li>
		<li>
		Comparative Product Portfolio Analysis
		</li>
		<li>
		Market Positioning/Share Analysis
		</li>
		<li>
		Mergers and Acquisitions Analysis
		</li>
	</ol>
	</li>
	<li>
	<h3>Global Market Company Profiles</h3>

	<ol>
		<li>
		Amicus Therapeutics *

		<ol>
			<li>
			Company Overview
			</li>
			<li>
			Product Portfolio and Description
			</li>
			<li>
			Key Highlights
			</li>
			<li>
			Financial Overview
			</li>
		</ol>
		</li>
		<li>
		ISU Abxis
		</li>
		<li>
		JCR Pharmaceuticals
		</li>
		<li>
		Biosidus
		</li>
		<li>
		Greenovation Biotech
		</li>
		<li>
		Lixte Biotechnology Holdings, Inc.
		</li>
		<li>
		Pharming Group N.V.
		</li>
		<li>
		Protalix BioTherapeutics
		</li>
		<li>
		Amicus
		</li>
		<li>
		Biomarin
		</li>
		<li>
		Sanofi
		</li>
		<li>
		Shire
		</li>
		<li>
		Celerion
		</li>
		<li>
		Orchard Therapeutics plc&nbsp;
		</li>
	</ol>
	</li>
	<li>
	<h3>DataM Intelligence</h3>

	<ol>
		<li>
		Appendix
		</li>
		<li>
		About Us and Services
		</li>
		<li>
		Contact Us
		</li>
	</ol>
	</li>
</ol>

<h3>List of Tables</h3>

Table 1&nbsp; Global Neurometabolic Disorders Market Value, By Disease Type, 2023,2027 &amp; 2031 ($ Million)

Table 2&nbsp; Global Neurometabolic Disorders Market Value, By Treatment Type, 2023,2027 &amp; 2031 ($ Million)

Table 3&nbsp; Global Neurometabolic Disorders Market Value, By Region, 2023,2027 &amp; 2031 ($ Million)

Table 4&nbsp; Global Neurometabolic Disorders Market Value, By Disease Type, 2023,2027 &amp; 2031 ($ Million)

Table 5&nbsp; Global Neurometabolic Disorders Market Value, By Disease Type, 2022-2031 ($ Million)

Table 6&nbsp; Global Neurometabolic Disorders Market Value, By Treatment Type, 2023,2027 &amp; 2031 ($ Million)

Table 7&nbsp; Global Neurometabolic Disorders Market Value, By Treatment Type, 2022-2031 ($ Million)

Table 8&nbsp; Global Neurometabolic Disorders Market Value, By Region, 2023,2027 &amp; 2031 ($ Million)

Table 9&nbsp; Global Neurometabolic Disorders Market Value, By Region, 2022-2031 ($ Million)

Table 10&nbsp; North America Neurometabolic Disorders Market Value, By Disease Type, 2022-2031 ($ Million)

Table 11&nbsp; North America Neurometabolic Disorders Market Value, By Treatment Type, 2022-2031 ($ Million)

Table 12&nbsp; North America Neurometabolic Disorders Market Value, By Country, 2022-2031 ($ Million)

Table 13&nbsp; South America Neurometabolic Disorders Market Value, By Disease Type, 2022-2031 ($ Million)

Table 14&nbsp; South America Neurometabolic Disorders Market Value, By Treatment Type, 2022-2031 ($ Million)

Table 15&nbsp; South America Neurometabolic Disorders Market Value, By Country, 2022-2031 ($ Million)

Table 16&nbsp; Europe Neurometabolic Disorders Market Value, By Disease Type, 2022-2031 ($ Million)

Table 17&nbsp; Europe Neurometabolic Disorders Market Value, By Treatment Type, 2022-2031 ($ Million)

Table 18&nbsp; Europe Neurometabolic Disorders Market Value, By Country, 2022-2031 ($ Million)

Table 19&nbsp; Asia-Pacific Neurometabolic Disorders Market Value, By Disease Type, 2022-2031 ($ Million)

Table 20&nbsp; Asia-Pacific Neurometabolic Disorders Market Value, By Treatment Type, 2022-2031 ($ Million)

Table 21&nbsp; Asia-Pacific Neurometabolic Disorders Market Value, By Country, 2022-2031 ($ Million)

Table 22&nbsp; Middle East &amp; Africa Neurometabolic Disorders Market Value, By Disease Type, 2022-2031 ($ Million)

Table 23&nbsp; Middle East &amp; Africa Neurometabolic Disorders Market Value, By Treatment Type, 2022-2031 ($ Million)

Table 24&nbsp; Amicus Therapeutics: Overview

Table 25&nbsp; Amicus Therapeutics: Product Portfolio

Table 26&nbsp; Amicus Therapeutics: Key Developments

Table 27&nbsp; ISU Abxis: Overview

Table 28&nbsp; ISU Abxis: Product Portfolio

Table 29&nbsp; ISU Abxis: Key Developments

Table 30&nbsp; JCR Pharmaceuticals: Overview

Table 31&nbsp; JCR Pharmaceuticals: Product Portfolio

Table 32&nbsp; JCR Pharmaceuticals: Key Developments

Table 33&nbsp; Biosidus: Overview

Table 34&nbsp; Biosidus: Product Portfolio

Table 35&nbsp; Biosidus: Key Developments

Table 36&nbsp; Greenovation Biotech: Overview

Table 37&nbsp; Greenovation Biotech: Product Portfolio

Table 38&nbsp; Greenovation Biotech: Key Developments

Table 39&nbsp; Lixte Biotechnology Holdings, Inc.: Overview

Table 40&nbsp; Lixte Biotechnology Holdings, Inc.: Product Portfolio

Table 41&nbsp; Lixte Biotechnology Holdings, Inc.: Key Developments

Table 42&nbsp; Pharming Group N.V.: Overview

Table 43&nbsp; Pharming Group N.V.: Product Portfolio

Table 44&nbsp; Pharming Group N.V.: Key Developments

Table 45&nbsp; Protalix BioTherapeutics: Overview

Table 46&nbsp; Protalix BioTherapeutics: Product Portfolio

Table 47&nbsp; Protalix BioTherapeutics: Key Developments

Table 48&nbsp; Amicus: Overview

Table 49&nbsp; Amicus: Product Portfolio

Table 50&nbsp; Amicus: Key Developments

Table 51&nbsp; Biomarin: Overview

Table 52&nbsp; Biomarin: Product Portfolio

Table 53&nbsp; Biomarin: Key Developments

<h3>List of Figures</h3>

Figure 1&nbsp;&nbsp;Global Neurometabolic Disorders Market Share, By Disease Type, 2022 &amp; 2031 (%)

Figure 2&nbsp;&nbsp;Global Neurometabolic Disorders Market Share, By Treatment Type, 2022 &amp; 2031 (%)

Figure 3&nbsp;&nbsp;Global Neurometabolic Disorders Market Share, By Region, 2022 &amp; 2031 (%)

Figure 4&nbsp;&nbsp;Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 5&nbsp;&nbsp;Global Neurometabolic Disorders Market Y-o-Y Growth, By Disease Type, 2018-2029 (%)

Figure 6&nbsp;&nbsp;Amino Acid Disorders: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 7&nbsp;&nbsp;Carbohydrate Metabolism Disorders: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 8&nbsp;&nbsp;Mitochondrial Disorders: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 9&nbsp;&nbsp;Peroxisomal Disorders : Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 10&nbsp;&nbsp;Lysosomal Storage Disorders: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 11&nbsp;&nbsp;Phenylketonuria: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 12&nbsp;&nbsp;Maple Syrup Urine Disease: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 13&nbsp;&nbsp;Others: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 14&nbsp;&nbsp;Diabetes: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 15&nbsp;&nbsp;Friedreich Ataxia : Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 16&nbsp;&nbsp;Wilson Disease: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 17&nbsp;&nbsp;Zellweger Syndrome : Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 18&nbsp;&nbsp;Adrenoleukodystrophy: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 19&nbsp;&nbsp;Hunter Syndrome: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 20&nbsp;&nbsp;Niemann-Pick Disease: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 21&nbsp;&nbsp;Tay-Sachs Disease: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 22&nbsp;&nbsp;Gaucher Disease: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 23&nbsp;&nbsp;Fabry Disease: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 24&nbsp;&nbsp;Krabbe Disease: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 25&nbsp;&nbsp;Global Neurometabolic Disorders Market Y-o-Y Growth, By Treatment Type, 2018-2029 (%)

Figure 26&nbsp;&nbsp;Food Supplements: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 27&nbsp;&nbsp;Drugs: Global Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 28&nbsp;&nbsp;Global Neurometabolic Disorders Market Y-o-Y Growth, By Region, 2018-2029 (%)

Figure 29&nbsp;&nbsp;North America Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 30&nbsp;&nbsp;North America Neurometabolic Disorders Market Share, By Disease Type, 2022 &amp; 2031 (%)

Figure 31&nbsp;&nbsp;North America Neurometabolic Disorders Market Share, By Treatment Type, 2022 &amp; 2031 (%)

Figure 32&nbsp;&nbsp;North America Neurometabolic Disorders Market Share, By Country, 2022 &amp; 2031 (%)

Figure 33&nbsp;&nbsp;South America Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 34&nbsp;&nbsp;South America Neurometabolic Disorders Market Share, By Disease Type, 2022 &amp; 2031 (%)

Figure 35&nbsp;&nbsp;South America Neurometabolic Disorders Market Share, By Treatment Type, 2022 &amp; 2031 (%)

Figure 36&nbsp;&nbsp;South America Neurometabolic Disorders Market Share, By Country, 2022 &amp; 2031 (%)

Figure 37&nbsp;&nbsp;Europe Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 38&nbsp;&nbsp;Europe Neurometabolic Disorders Market Share, By Disease Type, 2022 &amp; 2031 (%)

Figure 39&nbsp;&nbsp;Europe Neurometabolic Disorders Market Share, By Treatment Type, 2022 &amp; 2031 (%)

Figure 40&nbsp;&nbsp;Europe Neurometabolic Disorders Market Share, By Country, 2022 &amp; 2031 (%)

Figure 41&nbsp;&nbsp;Asia-Pacific Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 42&nbsp;&nbsp;Asia-Pacific Neurometabolic Disorders Market Share, By Disease Type, 2022 &amp; 2031 (%)

Figure 43&nbsp;&nbsp;Asia-Pacific Neurometabolic Disorders Market Share, By Treatment Type, 2022 &amp; 2031 (%)

Figure 44&nbsp;&nbsp;Asia-Pacific Neurometabolic Disorders Market Share, By Country, 2022 &amp; 2031 (%)

Figure 45&nbsp;&nbsp;Middle East &amp; Africa Neurometabolic Disorders Market Value, 2022-2031 ($ Million)

Figure 46&nbsp;&nbsp;Middle East &amp; Africa Neurometabolic Disorders Market Share, By Disease Type, 2022 &amp; 2031 (%)

Figure 47&nbsp;&nbsp;Middle East &amp; Africa Neurometabolic Disorders Market Share, By Treatment Type, 2022 &amp; 2031 (%)

Figure 48&nbsp;&nbsp;Amicus Therapeutics: Financials

Figure 49&nbsp;&nbsp;ISU Abxis: Financials

Figure 50&nbsp;&nbsp;JCR Pharmaceuticals: Financials

Figure 51&nbsp;&nbsp;Biosidus: Financials

Figure 52&nbsp;&nbsp;Greenovation Biotech: Financials

Figure 53&nbsp;&nbsp;Lixte Biotechnology Holdings, Inc.: Financials

Figure 54&nbsp;&nbsp;Pharming Group N.V.: Financials

Figure 55&nbsp;&nbsp;Protalix BioTherapeutics: Financials

Figure 56&nbsp;&nbsp;Amicus: Financials

Figure 57&nbsp;&nbsp;Biomarin: Financials

Neurometabolic Disorders Market Size, Share, Industry, Forecast and outlook (2024-2031)

Metabolic Disorders Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 11

Starting from

Frontotemporal Disorders Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2024 January 19

Starting from

Optical Disorders Drugs Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2024 February 01

Starting from